Hints and tips:
...The chairman of Metric Media Foundation is listed as Rakesh Donthineni, an Oakland-based orthopaedic surgeon....
...Lack of scale is not necessarily a disadvantage, Medacta’s 32 per cent operating margins are in line with large peers such as Zimmer Biomet and DePuy Synthes....
...Besides Stryker, other leaders in the industry include Johnson & Johnson, which acquired orthopaedic device maker Synthes for $21.3bn in 2012, and Zimmer Biomet, which was formed by a $14bn takeover in 2014...
...Johnson & Johnson or Zimmer Biomet would be likely to trigger antitrust investigations) but also from a strategic viewpoint....
...Forecast sales for Zimmer Biomet in 2018 are only 2 per cent higher than the combined 2014 sales of the two separate companies....
...The orthopaedics market has been convulsed by the $13bn merger of Zimmer and Biomet, completed last year, and restructuring at J&J, which last month announced 3,000 job cuts in its medical devices unit....
...Zimmer and Biomet will cut costs by merging, he admits, but adds: “Will they grow their top line? I bet it doesn’t work.”...
...S&N added 1.8 per cent to £11.65 on talk of interest from Johnson & Johnson, whose DePuy orthopaedic subsidiary was pushed to number three in the market for knee implants by Zimmer’s purchase of Biomet....
...Credit Suisse told clients: “There is ongoing M&A activity and industry consolidation in orthopaedics....
...It valued the orthopaedic devices maker at £12.25 on a standalone basis, with a further 200p to 250p possible from M&A....
...Bid target Smith & Nephew held firm at £11.76, up 0.1 per cent, even after US peer Biomet kicked off the reporting season for the orthopaedic device makers with worse than expected figures for both hip and...
...Orthopaedics maker Smith & Nephew faded 2 per cent to £11.10 after Morgan Stanley played down hopes of a bid from US peer Stryker....
...Mr Bohuon’s comments come a week after Indiana-based Zimmer, maker of the eponymous walking frame, agreed to buy orthopaedic products group Biomet for $13bn....
...News of the deal follows speculation that S&N might spin off or sell its orthopaedics division....
...Analysts saw the potential tie-up as a defensive move in response to Zimmer’s bid for Biomet to create the world’s biggest orthopaedics maker....
...Listed competitors, Stryker Corp in the US and UK-based Smith & Nephew, Europe’s largest orthopaedic device maker, are valued at about 8.5 times ebitda, which would give Biomet a theoretical valuation of...
...Smith & Nephew was up 0.8 per cent to 775p after US peer Biomet began reporting season for the orthopaedics makers with broadly reassuring numbers showing hip and knee volumes remaining steady from the...
...We will outperform the market in woundcare, trauma and sports medicine, but will be slightly below the market in orthopaedic reconstruction.”...
...J&J’s orthopaedics division posted flat underlying sales as a market uptick in the fourth quarter failed to continue into the new year....
...Rival orthopaedics maker Biomet said overnight that sales of hip and knee implants had slowed sharply in the quarter ending August....
...The network was one of several unearthed during a probe by the US in 2007 into corruption by medical device groups in Greece, with probes continuing against rivals including Biomet, Stryker, Zimmer and Medtronic...
...An unexpectedly positive trading update from US orthopaedics maker Biomet helped lifted sector peer Smith & Nephew by 2 per cent to 587½p....
...Jude, Boston Scientific) underperforming badly while orthopaedic specialists (Stryker, Smith & Nephew, and Zimmer) have fared better....
...S&N is a world leader in its field and specialises in advanced wound-care products such as dressings and gels, endoscopy and other medical devices, as well as its orthopaedics business....
...Well, a deal between two leading orthopaedic implant manufacturers makes a lot of sense says Merrill Lynch … As Biomet’s weak orthopaedic results for 2QFY11 (6th January) highlighted, the fundamental outlook...
International Edition